Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

.We know Chang was working on CIT at U of Florida, on his own volition...What was going on in January 2011 in India and why was the new version of CIT halted in July 2011 in the USA /Florida? ..The answer...By Jason Crew and not the storyteller you understand...

Radient Pharmaceuticals: speculation intensifies over commercial potential of Onko-Sure cancer diagnostic test
13th Jan 2011, 7:54 pm by Jason Chew

Radient has also begun rolling out a lung cancer screening kit called LC Sentinal in the US with partner, Provista Diagnostics. This kit was co-developed by the two companies and is based on the same technology as Onko-Sure. Provista intends to market the kit initially as a laboratory developed test, in which case, each individual laboratory using the kit will need to validate the test prior to its use. The companies will seek FDA approval for the kit in 2011; once this happens, kits can be marketed much more broadly without the need for validations from individual labs.

A partner has also been found to further the development of the CIT vaccine technology. In December 2010, a new subsidiary, NuVax Therapeutics was formed in collaboration with biotechnology company, Jaiva Technologies to develop the technology as well as additional immunotherapies.


http://www.proactiveinvestors.com/companies/news/11423/radient-pharmaceuticals-speculation-intensifies-over-commercial-potential-of-onko-sure-cancer-diagnostic-test-11423.html


http://www.biospace.com/News/radient-pharmaceuticals-strategic-partner-jaiva/185308

Goldseeker also Said:

"As for CIT in India -- Nobody in India is doing anything with CIT. Not SRL, not Metropolis, not anyone. There are no CIT Phase II or Phase III studies."

Phase II started in India in 2010..Phase III should be completed by now...someone needs to research in India and not Florida you understand...Nuvax Out..Jaiva and strategic Partner in India Still IN.....ahoooooooooooooooooooooooooooooo

Radient Pharmaceuticals Strategic Partner Jaiva Technologies Plans to Submit Application for Phase II Human Clinical Trials for Non-Small Cell Lung Carcinoma; Advancing Commercialization of RPC's CIT(TM) Cancer Vaccine in India


6/24/2010

TUSTIN, CA--(Marketwire - June 24, 2010) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company, and Jaiva Technologies, Inc. ("Jaiva"), a US-based biotechnology company focused on the research and development, distribution, marketing and sales of promising third-party healthcare technology products, including RPC's CIT cancer therapy and vaccine, announced today that Jaiva plans to submit a clinical trial application to the Central Drugs Standard Control Organization (CDSCO) in India to commence human phase II trials for RPC's Combination Immunogene Therapy (CIT) technology as a vaccine therapy for non-small cell lung carcinoma (NSCLC).


According to Decision Resources, Inc., the NSCLC drug market is forecasted to reach US$4.1B by FY2014. RPC and Jaiva expect to begin product commercialization by FY2015, following the successful completion of these trials. Jaiva has indicated they anticipate securing 5% of the lung cancer treatment market share, or approximately US$200M in CIT sales by 2017; and approximately 10% market share or US$400M of the forecasted market by FY2020.



Mr. Douglas MacLellan, Executive Chairman and CEO of RPC, commented, "This submission to the CDSCO for approval to commence human clinical trials for a general non-small cell lung carcinoma vaccine is a major milestone for Radient Pharmaceuticals and will continue to bring strategic value to our company and its stakeholders as we move our cancer products and programs toward commercialization. Upon receiving CDSCO approval for this clinical trial application, we will then commence phase III trials in India and the United States."


According to Dr. Umesh Bhatia, Jaiva CEO, "We are extremely excited to initiate this important trial with the CDSCO in India. CIT has tremendous potential benefit in treating NSCLC patients, and through the successful completion of this phase II trial we will initiate phase III in India and in the USA."

http://www.biospace.com/News/radient-pharmaceuticals-strategic-partner-jaiva/185308

What State in the USA do you think the Phase III is being developed in?